Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vas Narasimhan

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Nature Reviews. Drug Discovery|January 1, 2016
Vas NarasimhanVas Narasimhan, Asher Mullard
Clinical Pharmacology and Therapeutics|April 16, 2020
Leading a Digital Transformation in the Pharmaceutical Industry: Reimagining the Way We Work in Global Drug DevelopmentLuca A Finelli, Vas Narasimhan
BMJ (Clinical Research Ed.)|April 19, 2013
Is the adjuvant solely to blame?Theodore Tsai, Giuseppe Del Giudice, Antonio Crucitti, et al.
Annals of Global Health|November 29, 2023
Bridging the Access Gap for Comprehensive Sickle Cell Disease Management Across Sub-Saharan Africa: Learnings for Other Global Health Interventions?Lutz Hegemann, Vas Narasimhan, Kwaku Marfo, et al.
Science Translational Medicine|May 3, 2014
A cell culture-derived MF59-adjuvanted pandemic A/H7N9 vaccine is immunogenic in adultsStephan A Bart, Matthew Hohenboken, Giovanni Della Cioppa, et al.
Vaccine|July 4, 2014
Prevention of group B streptococcal disease in the first 3 months of life: would routine maternal immunization during pregnancy be cost-effective?Gerry Oster, John Edelsberg, Kalin Hennegan, et al.
Vaccine|July 22, 2014
Comparison of the safety and immunogenicity of an MF59®-adjuvanted with a non-adjuvanted seasonal influenza vaccine in elderly subjectsSharon E Frey, Mari Rose Aplasca-De Los Reyes, Humberto Reynales, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 14, 2017
Antibody Kinetics and Response to Routine Vaccinations in Infants Born to Women Who Received an Investigational Trivalent Group B Streptococcus Polysaccharide CRM197-Conjugate Vaccine During PregnancyShabir A Madhi, Anthonet Koen, Clare L Cutland, et al.
The Lancet. Infectious Diseases|May 4, 2016
Safety and immunogenicity of an investigational maternal trivalent group B streptococcus vaccine in healthy women and their infants: a randomised phase 1b/2 trialShabir A Madhi, Clare L Cutland, Lisa Jose, et al.
Vaccine|September 17, 2014
Enhanced and persistent antibody response against homologous and heterologous strains elicited by a MF59-adjuvanted influenza vaccine in infants and young childrenTerry Nolan, Lulu Bravo, Ana Ceballos, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Nature Reviews. Drug Discovery|January 1, 2016
Vas NarasimhanVas Narasimhan, Asher Mullard
Clinical Pharmacology and Therapeutics|April 16, 2020
Leading a Digital Transformation in the Pharmaceutical Industry: Reimagining the Way We Work in Global Drug DevelopmentLuca A Finelli, Vas Narasimhan
BMJ (Clinical Research Ed.)|April 19, 2013
Is the adjuvant solely to blame?Theodore Tsai, Giuseppe Del Giudice, Antonio Crucitti, et al.
Annals of Global Health|November 29, 2023
Bridging the Access Gap for Comprehensive Sickle Cell Disease Management Across Sub-Saharan Africa: Learnings for Other Global Health Interventions?Lutz Hegemann, Vas Narasimhan, Kwaku Marfo, et al.
Science Translational Medicine|May 3, 2014
A cell culture-derived MF59-adjuvanted pandemic A/H7N9 vaccine is immunogenic in adultsStephan A Bart, Matthew Hohenboken, Giovanni Della Cioppa, et al.
Vaccine|July 4, 2014
Prevention of group B streptococcal disease in the first 3 months of life: would routine maternal immunization during pregnancy be cost-effective?Gerry Oster, John Edelsberg, Kalin Hennegan, et al.
Vaccine|July 22, 2014
Comparison of the safety and immunogenicity of an MF59®-adjuvanted with a non-adjuvanted seasonal influenza vaccine in elderly subjectsSharon E Frey, Mari Rose Aplasca-De Los Reyes, Humberto Reynales, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 14, 2017
Antibody Kinetics and Response to Routine Vaccinations in Infants Born to Women Who Received an Investigational Trivalent Group B Streptococcus Polysaccharide CRM197-Conjugate Vaccine During PregnancyShabir A Madhi, Anthonet Koen, Clare L Cutland, et al.
The Lancet. Infectious Diseases|May 4, 2016
Safety and immunogenicity of an investigational maternal trivalent group B streptococcus vaccine in healthy women and their infants: a randomised phase 1b/2 trialShabir A Madhi, Clare L Cutland, Lisa Jose, et al.
Vaccine|September 17, 2014
Enhanced and persistent antibody response against homologous and heterologous strains elicited by a MF59-adjuvanted influenza vaccine in infants and young childrenTerry Nolan, Lulu Bravo, Ana Ceballos, et al.
Pageof 2